Shots: The CONCLUDE study assess the hypoglycemic risk with Tresiba (qd) vs insulin glargine U300 (qd) in 1,609 patients with T2D with/out oral anti-diabetic drugs, for 36wks. maintenance period and a total treatment period of up to 88wks. The CONCLUDE study result: reduction in the rate of severe hypoglycemia & nocturnal symptomatic hypoglycemia (80% & […]Read More
Shots: Novo Nordisk’s Tresiba has received an approval for indication expansion by Health Canada for the treatment of pediatric patients (>2 years of age) with Type 1 diabetes The expanded indication follows its last approval in Canada on Aug 2017 for the treatment of adults with Type 1 and Type 2 diabetes Tresiba (insulin degludec injection) is […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
